Successful maintenance on belatacept monotherapy without rejection

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully